When analyzing the induced pluripotent stem cell (iPSC) market, the technical aspects can often appear to be confusing. However, if you focus on a few key points of understanding, you’ll be able to understand key attributes that define the cell type, as well as their advantages and disadvantages. [Read more…]
The Cultured Meat Industry is a Nascent Industry that is Scaling Fast
The cultured meat industry is a young but revolutionary industry, with the potential to change agricultural practices and human meat consumption as we know it. Cultured meat refers to meat created using cell culture techniques within a laboratory or manufacturing facility. It is produced by growing stem cells collected from cattle, chicken, pigs, fish, lamb, and other livestock and then differentiating them into the various meat components, such as muscle (myocytes) and fat (adipose) tissue. [Read more…]
The Future of Stem Cell Therapeutics – Balancing Safety and Efficacy
What do we know of the safety and efficacy of stem cell therapeutics? Over 50 years have passed since the discovery of hematopoietic stem cells (bone marrow transplantation to cure diseases such as leukemia), over 24 years since the discovery of human embryonic stem cells (hESC), and 18 years since the discovery of induced pluripotent stem cells (iPS cells). There are now thousands of stem cell trials underway in clinics worldwide. Despite this experience, what do we actually know about the safety and efficacy of stem cell therapeutics? [Read more…]
FDA Grants RMAT to iRegene’s NouvNeu001, Making It World’s First iPSC Therapy with FTD and RMAT Recognitions
Designation underscores potential of chemically induced, off-the-shelf cell therapy to address high unmet need in Parkinson’s disease, following compelling Phase I clinical data
CHENGDU, China, Jan. 19, 2026 — iRegene Therapeutics Co., Ltd. (“iRegene” or the “Company”), a biotechnology company pioneering chemically induced allogeneic cell therapy, today announced that its lead product, NouvNeu001, has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. Food and Drug Administration (FDA) for the treatment of Parkinson’s disease (PD). [Read more…]
I Peace Announces Successful Generation of Human iPS Cells from NKT Cells and Commences Their Availability
February 6, 2026 – Palo Alto, CA – Leading GMP cell therapy CDMO I Peace, Inc., specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that it has successfully generated human induced pluripotent stem (iPS) cells from NKT cells and has begun offering them for research use. NKT cells are immune cells known to possess characteristics of both innate and adaptive immunity and to play important roles in cancer, infectious diseases, autoimmune disorders, and other conditions. The establishment of iPS cells derived from NKT cells is expected to significantly advance research in regenerative medicine and cancer therapy based on immune mechanisms. [Read more…]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 78
- Next Page »